2021 Sponsors

BioFIT is sponsored by companies from across the Life Sciences sector, reflecting the breadth of the event’s content, participants and partners.
Be one of them, contact us for further details.

Silver sponsors

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide… and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

Sanofi is a global life sciences company

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

For more information please visit our website www.sanofi.com.

Bronze sponsors

Alzprotect is a biopharmaceutical company that develops drug candidates, from their discovery to clinical trials, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and tauopathies such as Progressive Supranuclear Palsy (PSP).

Alzprotect has developed specific global-level expertise in tauopathies, where neuronal degeneration is a consequence of an abnormal accumulation of hyperphosphorylated Tau proteins combined to neuroinflammation: Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease (AD).

Their expertise led to the discovery of several molecules with novel mechanisms of action, such as AZP2006 that shows potent and promising effects to control neurodegeneration.

Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Our significant investment in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

FINDMED is a consortium of 18 French leading research institutions involved in healthcare at large and that have got the “Carnot” label for their ability to conduct R&D partnerships with companies . FINDMED’s mission is to help French companies, in particular start-up and SMEs, to access the expertise and the technological platforms of its members. FINDMED is therefore companies’ R&D partner for their innovation projects, whether they be biotech and/or medtech.

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor* in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp® in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. Nasdaq and Euronext: GNFT.
* Elafibranor is an investigational compound that has not been reviewed and has not received approval by any regulatory authority

Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. We are committed to the discovery and development of innovative treatments for diabetes, obesity, haemophilia, NASH, atherosclerosis, heart failure, chronic kidney disease as well as some rare blood or endocrine diseases. We are seeking partnerships in all these indications. From molecule to market, our focus is on the patient. We are also committed to environmental and social responsibility.

About Pfizer: Breakthroughs That Change Patients’ Lives 
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.
In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer NewsLinkedInYouTube and like us on Facebook at Facebook.com/Pfizer

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed over 100,000 people worldwide.

Alongside the broad internal pipeline, external innovation has always been a critical component of the Roche research and development strategy. Only in 2020, Roche entered into 92 new partnerships and is managing over 220 ongoing alliances worldwide.